Now I have all the information needed. Let me produce the consolidated final review.

## Summary

The paper proposes SCREENER, a fully self-supervised framework for unsupervised pathology segmentation in 3D CT images. It consists of three components: (1) a domain-specific self-supervised descriptor model (trained with SimCLR or VICReg) that produces dense feature maps invariant to local augmentations, (2) a masking-invariant condition model that encodes global contextual information, and (3) a conditional density model (Gaussian or normalizing flow) that estimates per-pixel anomaly scores as negative log-likelihoods. The method is trained on over 30,000 3D CT volumes from NLST, AMOS, and AbdomenAtlas without using any annotations, and evaluated on four test sets (LIDC, MIDRC-RICORD-1a, KiTS, LiTS) totaling 1,820 scans. The key innovations are replacing ImageNet-pretrained feature extractors with CT-specific self-supervised descriptors, and introducing learned conditioning variables via a masking invariance objective to simplify density estimation.

## Strengths

- **Domain-specific self-supervised descriptors dramatically outperform ImageNet-based features for medical UVAS.** Table 4 demonstrates that the VICReg descriptor (d=32) achieves 0.883 AUROC on LIDC, whereas MSFlow with ImageNet-pretrained features drops to 0.649. This cleanly supports the paper's central claim that ImageNet features suffer from domain shift for 3D medical CT and that self-supervised pre-training on in-domain data is a major improvement.

- **Learned masking-invariant conditioning enables a simple Gaussian density model to compete with expressive flow-based models.** Table 3 shows that without conditioning, the Gaussian model achieves 0.726 AUROC on LIDC; with the proposed condition model it reaches 0.828, while sin-cos positional encoding only reaches 0.733. This validates the contribution that data-driven conditioning variables simplify density estimation, and the result that the Gaussian+condition model approaches the flow model's performance (0.883) is practically significant.

- **First large-scale evaluation of UVAS on 3D CT images with consistent SOTA performance across four diverse pathologies.** Table 2 reports that SCREENER achieves the best AUROC and AUPRO on all four test sets spanning lung cancer, pneumonia, liver tumors, and kidney tumors. The scale (30k+ training volumes, 1,820 test volumes) is unusual and provides a credible benchmark for future work in this space.

- **Addresses realistic training conditions where datasets unavoidably contain unlabeled pathologies.** The paper explicitly trains on datasets without filtering out anomalies (Section 4.1), unlike reconstruction-based and synthetic-anomaly methods that require anomaly-free training sets. This practical design choice is well-motivated by the difficulty of curating truly pathology-free CT datasets at scale.

- **Qualitative results highlight detection of pathologies absent from ground-truth masks.** Figure 3 shows SCREENER identifying a pneumothorax missed by annotations, directly illustrating why standard segmentation metrics like Dice would be inappropriate and why ranking metrics are necessary in this setting.

## Weaknesses

### Fatal
None.

### Major
None. The paper's core contributions are supported by the evidence provided. The issues below are addressable in revision and do not invalidate the core claims.

### Minor

- **Mismatch between "pathology segmentation" framing and ranking-based evaluation.** The title and introduction frame the task as "pathology segmentation," yet the evaluation uses only pixel-level AUROC and AUPRO—metrics that measure how well anomaly scores rank pixels rather than whether they produce accurate binary segmentations. The paper addresses this directly in Section 4.2, providing a principled justification (incomplete annotations make Dice/Hausdorff infeasible). However, the critic's deeper point stands: the same incomplete-annotation problem also compromises the specificity estimates used by AUROC/AUPRO (the paper uses "random pixels that do not belong to the annotated tumors which are mostly normal"), and no thresholded segmentation evaluation is provided on any subset. The method demonstrably produces localized score maps, but the claim of "segmentation" in the title is stronger than what the evaluation protocol fully validates. This is primarily a presentation/claims-calibration issue.

- **Condition model's claimed anomaly invariance is asserted but not directly validated.** Section 3.2 states that the condition model is "designed to ignore the presence of pathologies" because pathological content "cannot be consistently inferred from masked views." The ablation studies show that conditioning improves density estimation, which is consistent with this property, but does not directly test it. A condition model that *does* encode anomalies could still improve density estimation by making the conditional distribution more peaked. Without a targeted analysis—e.g., comparing condition vectors from pathological vs. healthy regions, or measuring mutual information between condition vectors and anomaly presence—the claimed property remains a plausible intuition rather than an established fact. This weakens the theoretical justification but does not invalidate the empirical results.

- **Baseline implementation details are insufficient for reproducibility or fairness assessment.** The paper implements 3D versions of five baseline methods (AE, f-anoGAN, DRAEM, MOOD-Top1, MSFlow) but provides no information about hyperparameter selection, tuning procedures, training convergence checks, or validation protocols for these methods. For density-based methods like MSFlow, the choice of latent dimensionality, flow architecture, and learning rate can substantially affect results. For synthetic-anomaly methods (DRAEM, MOOD), the simulation strategy strongly influences performance. Without evidence that baselines were reasonably tuned, the reported large margins (e.g., 0.889 vs. 0.763 AUROC on LIDC) may partly reflect undertuned comparisons. Additionally, no confidence intervals or statistical tests are reported for any method, making the variability of results unknown. This is an evidential gap that tempers the SOTA claim.

- **Missing architectural and training details that hinder reproducibility.** The paper does not specify the backbone architecture of the descriptor/condition models (e.g., type of 3D CNN, number of layers, downsampling factors), the exact values of H, W, S (crop dimensions), the architecture of the normalizing flow (coupling layer type, number of flow steps, parameter count), the training hyperparameters (learning rate, batch size, optimizer, number of epochs), or the full set of augmentations used beyond "color jitter." These omissions are not fatal (the approach is conceptually clear) but make independent re-implementation needlessly difficult.

### Trivial

- The paper claims "first large-scale study of UVAS in 3D CT images" — this is an empirical claim that cannot be verified from the paper's content alone; it would be more appropriately worded as "to our knowledge, the first."

## Nice-to-Haves

- **Binarized segmentation evaluation on a clean subset:** If a test subset with exhaustive annotations can be identified (e.g., by manual inspection of a small sample), computing Dice or IoU would strengthen the segmentation claim and address the title/metrics mismatch.
- **Direct visualization of condition model invariance:** PCA or similarity analysis of condition vectors from pathological vs. healthy regions would validate the claimed property and strengthen the theoretical contribution.
- **Ablation of masking ratio in condition model training:** The paper uses masking augmentation (Section 3.2) but does not study its effect; this would clarify whether masking is essential or incidental to the condition model's behavior.
- **Confidence intervals or error bars** would allow readers to assess the reliability of the reported margins over baselines.

## Removed Points

These points are flagged for removal; treat them with caution:

- *Harsh critic's point about "the assumption that pathological patterns are rarer than healthy patterns is not quantified"* — The paper states this as an explicit assumption motivating the density-based approach. Quantifying it is a nice-to-have, not a weakness of the method.
- *Harsh critic's point about "no confidence intervals, no statistical tests"* — Per soft rules, single-run evaluation without confidence intervals is standard practice in large-scale UVAS benchmarks (e.g., MVTecAD). This is a presentation limitation, not a methodological flaw.
- *Harsh critic's "Section-by-Section Notes" about training/test splits not being described* — The paper describes the datasets used and their sources (Section 4.1), which is standard practice for public benchmark datasets.
- *Harsh critic's request for "failure analysis on false positives" and "thresholded segmentation maps"* — These are enhancements, not weaknesses of the existing work.
- *Strength Finder's generic statement about "comprehensive ablation studies"* — While the ablations are reasonably broad, this phrasing is generic. The specific ablation results are already captured in the strengths above.

## Novel Insights

Beyond the paper's own contributions, the reviews surface a nuanced tension that the paper partially engages but does not fully resolve: the choice to frame the task as "pathology segmentation" while evaluating only with ranking metrics (AUROC/AUPRO) is defended on the grounds of incomplete annotations, but this defense applies only to *some* of the metrics' limitations. The paper argues that Dice penalizes correct detection of unannotated pathologies, but the same unannotated pathologies distort the specificity estimates that AUROC and AUPRO rely on (since those pixels are counted as "normal"). Neither metric set is clean in this setting. What the paper lacks is a direct argument—or targeted experiment—showing that its anomaly maps are sharp and thresholdable, not just diffuse rankings. This tension between evaluation ideals and real-world annotation constraints is a genuinely difficult methodological challenge for the field, and the paper would be strengthened by engaging with it more explicitly rather than treating AUROC/AUPRO as a simple solution.

## Suggestions

1. **Calibrate the claims to match the evaluation.** Replace or qualify "pathology segmentation" in the title and abstract (e.g., "unsupervised pathology localization" or "anomaly score mapping"), or add a supplementary experiment on a subset with near-exhaustive annotations (e.g., from the Medical Segmentation Decathlon) to demonstrate binarized segmentation capability.

2. **Directly validate the condition model's anomaly invariance.** Compute and report cosine similarity or distributional divergence (MMD) of condition vectors from pathological vs. healthy regions on a held-out set with complete masks. This would convert a plausible intuition into an established property.

3. **Document baseline tuning.** Add a brief description of how each baseline was configured, including hyperparameter search ranges (if any), the validation metric used, and final selected hyperparameters. Report performance variance (even from a few runs) to establish that margins are robust.

4. **Add architectural specifics to the main paper or supplement.** Backbone architecture, crop dimensions H/W/S, normalizing flow parameterization, and training hyperparameters should be documented to support reproducibility.

## Score and Decision

The paper presents a well-motivated framework with a clear conceptual contribution (domain-specific SSL descriptors + learned conditioning variables for density-based UVAS) and provides extensive empirical evaluation at an impressive scale. The main weaknesses are: (1) a tension between the "segmentation" framing and the ranking-based evaluation, (2) the condition model's claimed invariance property is asserted but unverified, and (3) insufficient detail about baseline configurations limits the interpretability of reported margins. None of these are fatal; the contributions are genuine and the evidence for the core claims is substantial. However, the paper would benefit from addressing the segmentation/evaluation mismatch and providing more rigorous validation of the condition model.

MY FINAL SCORE: <pineapple>6.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>